Cortexyme says COR388 reduced levels of ApoE protein in Phase I study
Cortexyme announced the presentation of "new data supporting the on-target activity of COR388, its lead investigational medicine, and linking the "gingipain hypothesis" for Alzheimer's disease to the significance of the APOE gene as a major risk factor for the disease." Michael Detke, the company's Chief Medical Officer, detailed the results in an oral presentation at the Clinical Trials in Alzheimer's Disease meeting. Cortexyme's Phase 1 clinical development program for COR388 included cohorts of healthy volunteers and subjects with Alzheimer's disease. In addition to assessing safety and initial clinical activity, investigators also assessed the level of ApoE fragmentation in the CSF of nine subjects with Alzheimer's disease. Six subjects received 50mg of COR388 twice daily while three subjects received placebo. After 28 days, a statistically significant decrease in ApoE fragments was observed in subjects treated with COR388 versus those treated with placebo.